| Literature DB >> 28389855 |
Bee Eng Tan1, Ai Lee Lim2, Sow Lai Kan2, Chong Hong Lim2, Ying Fun Ng2, Serene Li Ching Tng3, Nur Syakirah Hassin3, Losshenee Chandran3, Norshahida Abdul Hamid3, Yvonne Yin Leng Lee4.
Abstract
To evaluate the achievement of treat-to-target (T2T) strategy in rheumatoid arthritis (RA) and identify factors associated with failed treatment target in a public rheumatology center. A cross-sectional study was conducted from June 2015 to February 2016. RA patients with disease duration greater than 2 years and under T2T for over a year were invited to the study. Demographic, clinical data, disease activity score of 28 joints (DAS28), and clinical disease activity index (CDAI) were collected in a single routine clinic visit. Treatment target was defined as DAS28 <3.2 or CDAI ≤10. Retrospective chart review was performed to determine reasons of failed treatment target. A total of 371 patients were recruited and 87.1% were female. Mean age and duration of RA were 53.5 years (SD 10.3) and 9.1 years (SD 6.6), respectively. Ethnic distribution was 49% Chinese, 27% Malay, and 24% Indian. T2T was achieved in 81.7% of the cohort. Non-Chinese ethnicity, positive rheumatoid factor, and treatment with three disease modifying anti-rheumatic drugs (DMARDs) were associated with failed treatment target. After controlling for covariates, Malay ethnicity (OR 2.96; 95% CI 1.47-5.96) and treatment with three DMARDs (OR 2.14; 95% CI 1.06-4.35) were associated with failed treatment target. There was no association between age, gender, duration of RA, BMI, smoking status, anti-citrulinated cyclic peptide, and achievement of T2T. The most common reasons of failed treatment target were inability to escalate DMARDs due to side effects (18.8%), lack of biologics fund (15.6%), and persistent disease despite optimum treatment (14.1%). T2T was successfully implemented. Malay patients need aggressive treatment adaptation to achieve optimal outcome.Entities:
Keywords: Clinical; Outcome; Rheumatoid arthritis; Routine; Treat-to-target
Mesh:
Substances:
Year: 2017 PMID: 28389855 DOI: 10.1007/s00296-017-3705-6
Source DB: PubMed Journal: Rheumatol Int ISSN: 0172-8172 Impact factor: 2.631